Jak2 inhibitors
Showing 1 - 25 of >10,000
Diabetes, Type 1 Trial (Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo)
Not yet recruiting
- Diabetes Mellitus, Type 1
- Abrocitinib 200 MG Oral Tablet
- +2 more
- (no location specified)
Feb 21, 2023
Immunoclassification, Psoriasis Trial in Hangzhou (adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors,
Recruiting
- Immunoclassification
- Psoriasis
- adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 16, 2022
COVID 19, Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors Trial
Withdrawn
- COVID 19
- Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors
- Hidroxicloroquina
- Control group
- (no location specified)
Sep 8, 2021
Janus Kinase Inhibitors Vs Tumor Necrosis Factor Inhibitors in
Not yet recruiting
- Rheumatoid Arthritis
- Observation
- (no location specified)
Oct 8, 2022
Rheumatoid Arthritis Trial ("apigenin" and "glycyrrhizin", "glycyrrhizin" and "boswellic acid", "")
Not yet recruiting
- Rheumatoid Arthritis
- "apigenin" and "glycyrrhizin"
- +2 more
- (no location specified)
Mar 27, 2023
Toxic Epidermal Necrolysis Trial in Fuzhou (Abrocitinib)
Recruiting
- Toxic Epidermal Necrolysis
-
Fuzhou, Fujian, ChinaDepartment of Dermatology, the First Affiliated Hospital of Fuji
Oct 31, 2023
Inpatient COVID-19 Treatments
Active, not recruiting
- COVID-19
- Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
-
New York, New YorkAetion, Inc.
Jan 12, 2023
Rheumatoid Arthritis Trial in Montpellier (Blood sample analysis of patients treated as standard care)
Recruiting
- Rheumatoid Arthritis
- Blood sample analysis of patients treated as standard care
-
Montpellier, FranceUniversity Hospital of Montpellier
Jan 12, 2022
JAK Inhibition in Ulcerative Colitis
Not yet recruiting
- Analyzing Immune Composition Changes Upon JAK Inhibitor Treatment of Ulcerative Colitis Patients
- JAK inhibitor treatment
- (no location specified)
Jul 11, 2022
Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.
Recruiting
- Arthritis, Rheumatoid
-
Sevilla, SpainHospital Universitario Virgen macarena
Nov 15, 2021
Alopecia Areata Trial in Sohag (Janus Kinase 1 and 2)
Recruiting
- Alopecia Areata
- Janus Kinase 1 and 2
-
Sohag, EgyptSohag University hospitals
May 12, 2023
JAK Inhibitors in Systemic Sclerosis-associated Interstitial
Recruiting
- Systemic Sclerosis
- Interstitial Lung Disease
-
Vandœuvre-lès-Nancy, Grand Est, FranceCHU Nancy
Jan 19, 2022
Rheumatoid Arthritis, Drug Use Trial in Hong Kong (biologic/targeted therapy)
Not yet recruiting
- Rheumatoid Arthritis
- Drug Use
- biologic/targeted therapy
-
Hong Kong, ChinaDepartment of Medicine, Tuen Mun Hospital
Jan 5, 2022
Carotid Plaque Burden in Philadelphia Negative
Recruiting
- Myeloproliferative Neoplasm
-
Sohag, EgyptFaculty of Medicine
Aug 14, 2023
Chronic GVHD, Chronic GVHD Trial run by the NCI (Baricitinib)
Active, not recruiting
- Chronic Graft vs Host Disease
- Chronic Graft-Versus-Host Disease
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Nov 29, 2022
BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of
Recruiting
- BCR-JAK2 Fusion Protein Expression
- +11 more
-
Palo Alto, California
- +3 more
Oct 5, 2022
Cicatricial Alopecia Trial in New York (PF-06700841, Placebo)
Recruiting
- Cicatricial Alopecia
- PF-06700841
- Placebo
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Aug 16, 2022
Abatacept, Treatment Compliance, Rheumatoid Arthritis Trial in Hangzhou (Janus Kinase Inhibitor, Abatacept)
Recruiting
- Abatacept
- +2 more
- Janus Kinase Inhibitor
- Abatacept
-
Hangzhou, Zhejiang, ChinaZhejiang Provincial People's Hospital
Jul 5, 2022
Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood
Not yet recruiting
- Severe Aplastic Anemia
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 23, 2023
Myelofibrosis, Moderate Thrombocytopenia Trial (Selinexor)
Not yet recruiting
- Myelofibrosis
- Moderate Thrombocytopenia
- (no location specified)
Jul 31, 2023
Polycystic Ovary Syndrome Trial (SGLT2 inhibitors combined with metformin, Placebo combined with metformin)
Not yet recruiting
- Polycystic Ovary Syndrome
- SGLT2 inhibitors combined with metformin
- Placebo combined with metformin
- (no location specified)
Jul 21, 2023
Atrial Fibrillation Trial (Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Rhythm control and anticoagulation)
Not yet recruiting
- Atrial Fibrillation
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Rhythm control and anticoagulation
- (no location specified)
Aug 14, 2023